Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Stock Information for Reviva Pharmaceuticals Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.